1093676-98-2

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 3-iodo-5-(1-Methyl-1H-pyrazol-4-yl)-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 3-iodo-5-(1-Methyl-1H-pyrazol-4-yl)-;3-iodo-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
• CAS NO: 1093676-98-2
• Molecular Formula: C₁₁H₉IN₄
• Molecular Weight: 324.12043
• Mol File: 1093676-98-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 3-iodo-5-(1-Methyl-1H-pyrazol-4-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 3-iodo-5-(1-Methyl-1H-pyrazol-4-yl)-(1093676-98-2)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 3-iodo-5-(1-Methyl-1H-pyrazol-4-yl)-(1093676-98-2)

Safety Data

• Hazardous Substances Data: 1093676-98-2(Hazardous Substances Data)

Usage

Heterocyclic compound

The structure of the compound contains multiple heteroatoms (atoms other than carbon and hydrogen), such as nitrogen and iodine.

Pyrrolopyridine core

The compound has a core structure consisting of a fusion of a pyrrole and a pyridine ring, which are both heterocyclic aromatic rings.

Iodine atom

The presence of an iodine atom in the compound may contribute to its unique properties and potential applications in medicinal chemistry.

Pyrazole ring

The compound contains a pyrazole ring, which is a five-membered heterocyclic ring with two nitrogen atoms and one carbon atom.

Methyl group

A methyl group (CH3) is attached to the pyrazole ring, which may influence the compound's reactivity and properties.

Potential applications in medicinal chemistry

Due to its unique structure and potential biological activities, this compound may be used in the development of new drugs and pharmaceutical compounds.

Building block for synthesis

The compound may serve as a building block for the synthesis of novel pharmaceutical compounds, allowing for the creation of new molecules with potential therapeutic applications.

Starting material for bioactive molecules

The compound can be used as a starting material for the preparation of bioactive molecules, which may have potential applications in the treatment of various diseases and conditions.

Need for further research

To fully understand the properties and potential uses of 1H-Pyrrolo[2,3-b]pyridine, 3-iodo-5-(1-methyl-1H-pyrazol-4-yl)-, additional research is necessary to explore its chemical properties, reactivity, and potential applications in medicinal chemistry and drug development.

Upstream product

• 918522-51-7 5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]-pyridine 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1093676-94-8 tert-butyl 3-iodo-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 1254926-77-6 tert-butyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,3-b]pyridine-1-carboxylate 
• 1450642-51-9 3-((4-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-1-yl) methyl)aniline 
• 1450642-53-1 3-((4-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-1-yl)methyl)phenol 
• 1450642-54-2 3-(1-(2,5-difluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1Hpyrrolo[2,3-b]pyridine; 
• 1450642-55-3 3-(1-(3,4-difluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1450642-56-4 3-(1-(3,5-difluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1Hpyrrolo[2,3-b]pyridine; 
• 1450642-57-5 C₂₂H₁₉FN₆ 
• 1450642-58-6 3-(1-(3-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b] pyridine 
• 1450642-59-7 C₂₃H₂₀F₂N₆ 
• 1450642-61-1 3-(1-(3,5-difluorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1450642-41-7 3-(1-(2-fluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1450642-42-8 3-(1-(3-fluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1450642-43-9 3-(1-(4-fluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.

5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

The present application relates to novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to prodrugs, derivatives, polymorphs, pharmaceutically acceptable salts and compositions comprising the said novel 5-(1H-pyrazol-4-yl)-1H- pyrrolo[2,3-b]pyridine compounds and their derivatives and their use in the treatment of various disorders.

3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS

Compounds of the formula I in which Q, R1, R2, R3 and R4 have the meanings indicated in Claim 1, are PDK1 inhibitors and can be employed for the treatment of tumours.